Search
Pareto Securities' Healthcare Conference: Cinclus Pharma is trying to usher in the next generation of acid reflux medicines with linaprazan glurate, a potassium-competitive acid blocker (P-CAB)
CEO Christer Ahlberg describes the shortcomings of today's medicines, and why he believes a P-CAB is the answer. This therapy originated...
Sep 16
Pareto Securities' Healthcare Conference: Biotech Analyst Dan Akschuti shares his take on the the conference and the state of biotech, and highlights key companies to watch in the region
He sees an optimistic turn after a challenging couple of years. Plus, highlighting Vicore, Camurus, Oculis, and BioArctic. Coverage...
Sep 16
Pareto Securities' Healthcare Conference: Saniona has built expertise in the ion channel space, in addition to its own work, it has partnerships with Jazz, Acadia, and others
CEO Thomas Feldthus describes the challenge of making ion channel medicines selective enough to avoid unwanted side effects. He walks us...
Sep 16
Pareto Securities' Healthcare Conference: BioArctic's CEO Gunilla Osswald highlights the company's brain transporter technology, the latest on Leqembi, and a Parkinson's program
She describes the transferrin receptor based brain transporter technology, which the company recently signed another new partner...
Sep 16
Pareto Securities' Healthcare Conference: Guard Therapeutics will have a key P2b trial read for its kidney protecting therapy RCM-035 in the 4th quarter - CEO Tobias Agervald walks us through it
He describes the science behind the A1M protein that this is based on, and how Guard has chosen kidney protection for patients who are...
Sep 16
Pareto Securities' Healthcare Conference: BioInvent has recently optimized its pipeline to focus on two key programs - BI-1808, the anti-TNFR2 antibody, and BI-1206, an FcγRIIB inhibitor
CEO Martin Welschof walks us through these two programs, which both target liquid and solid tumors. BI-1808 recently had data at EHA and...
Sep 16
Pareto Securities Healthcare Conference: Basilea is using its financial strength from two marketed products to develop its pipeline and acquire new products - it just received more BARDA funding today
CEO David Veitch walks us through the U.S. launch of Zevtera, and discusses where Cresemba is in its global commercial lifecycle. Plus,...
Sep 16
Takeda's CEO Christophe Weber describes the company's landmark phase 3 data that was presented at World Sleep Congress this week on its first-in-class orexin agonist for treating narcolepsy type 1
Christophe Weber discusses the 25 year journey from the discovery that orexin deficiency is the cause of narcolepsy to announcing two...
Sep 12
Leaders of Brandon Capital, a seed and VC firm formed in Australia and with an office in the UK as well, discuss their $290 million sixth fund
Founding Partner Stephen Thompson and Partner Jonathan Tobin list some of their recent investments, highlight the advantage of running...
Sep 12
Michael White, Head of Life Sciences & Healthcare, UK & Nordics at HSBC Innovation Banking, shares insights from his team's UK & Nordics: Life Sciences & Healthcare 1H 2025 Venture Financing Report
The report is full of data that shows where venture money is being invested in the region and by which investors, and includes these...
Sep 10
H.C. Wainwright Managing Director / Senior Healthcare Equity Research Analyst Ram Selvaraju shares Day 2 conference takeaways and discusses key companies he covers
He discusses Urogen, Oruka, Avadel, Aardvark, Summit, Instil Bio, and Crescent. Coverage brought to you by:
Sep 9
RAPT Therapeutics CEO Brian Wong walks us through the company's focus on inflammatory conditions, including a lead clinical program targeting IgE, and a next-generation CCR4 in preclinical development
He describes the lead program, RPT-904, which is designed to have a longer half-life and to be more selective than omalizumab. Plus, the...
Sep 9
Everest Medicines' CFO Ian Woo, and an expert in China biotech, describes the company's and the country's evolution from in-licensing assets from the West to developing its own innovative medicines
He discusses key assets Everest has in-licensed, including NEFCON and etrasimod, and describes the innovative work Everest is doing in...
Sep 9
Altimmune's CEO Vipin Garg discusses the company's work in MASH with the GLP-1 / glucagon dual agonist, pemvidutide
He explains the rationale for combining GLP-1 and glucagon for MASH, and discusses 24-week data that was released earlier this year....
Sep 9
Kicking off Day 2 of the H.C. Wainwright & Co. Global Investor Conference with Managing Director of Investment Banking James Cappuccio
He discusses the turn he is seeing in the fundraising environment for smaller companies, and their change from survival mode to funding...
Sep 9
Mineralys CEO John Congleton describes the rational of targeting aldosterone for hypertension and discusses his company's pivotal data
He describes the science behind aldosterone and Mineralys' program lorundrostat. The company had pivotal data earlier this year and plans...
Sep 8
H.C. Wainwright Senior Research Analyst Patrick Trucchio shares conference takeaways and discusses key companies he covers in the news
He shares his thoughts on Beam, Altimmune, Alnylam, Arrowhead, Cybin, Uniqure, and GH Research. Coverage brought to you by:
Sep 8
Catalyst Pharma CEO Richard Daly gives an overview of the company's three commercial products, and discusses the 'buy to build' model
He highlights the market penetration of FIRDAPSE, the differentiation he believes AGAMREE represents in the DMD space, and FYCOMPA. Plus,...
Sep 8
Ionis Pharmaceuticals' CEO Brett Monia discusses the recent trial success of olezarsen in severe hypertriglyceridemia, the approval of Dawnzera in HAE, and more
He describes the significance of the olezarsen trial success in this patient population, and next steps. Plus, how Dawnzera might compete...
Sep 8
H.C. Wainwright & Co.'s President of Capital Markets' Richard Gormley discusses the current environment for biotech
From the 2025 H.C. Wainwright Global Investor Conference, we discuss interest rates, M&A, data readouts, and more. Coverage brought to...
Sep 8
.png){kind=logo}
